← ANALYST RATINGS · TIPRANKS

Disc Medicine (IRON): analyst forecast and price target

$56.84 +0.34% close 16.10.26 · market cap $2.2B · Healthcare · Biotechnology IWM 0.05%
Price targets and ratings of

Analyst consensus

Strong Buy

11 Buy0 Hold0 Sell

Ratings of 11 analysts in the last 3 months

12-month forecast

$102+79.8% upside

Based on 11 price targets given in the last 3 months, the average target is $102, the highest $125, the lowest $86.00. The average is +79.8% from the last price of $56.84.

$60.00$80.00$100$120Jan 26AprJulOctJan 27AprJulOctHigh$125Average$102Low$86.00
Highest target $125 Average target $102 Lowest target $86.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $120 Buy +111.1% Reiterated 13.10.26on TipRanks 06:26 −6.4%next day −0.4%
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $120 Buy +111.1% Reiterated 21.09.26on TipRanks Sep 22 05:20 −3.0%next day 0.0% · 5 days −4.2%
Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% Truist Financial — Buy — Reiterated 21.09.26on TipRanks 07:55 −3.0%next day 0.0% · 5 days −4.2%
Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% Wells Fargo $79.00 → $86.00+8.9% Buy +51.3% Assigned 16.09.26on TipRanks 06:35 +2.3%next day −0.2% · 5 days −5.7%
Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% BMO Capital $100 Buy +75.9% Reiterated 10.09.26on TipRanks Sep 11 08:35 −2.5%next day −6.4% · 5 days −7.3%
Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% Leerink Partners $100 Buy +75.9% Reiterated 10.09.26on TipRanks 07:50 −2.5%next day −6.4% · 5 days −7.3%
Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% LifeSci Capital $100 Buy +75.9% Reiterated 10.09.26on TipRanks 07:35 −2.5%next day −6.4% · 5 days −7.3%
Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% Cantor Fitzgerald $125 Buy +119.9% Reiterated 31.08.26on TipRanks Sep 1 07:35 −1.4%next day +0.7% · 5 days −2.2%
Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% Morgan Stanley $85.00 → $90.00+5.9% Buy +58.3% Assigned 17.08.26on TipRanks 08:55 +2.0%next day +0.9% · 5 days +2.3%
David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% Wedbush $88.00 Buy +54.8% Reiterated 11.08.26on TipRanks 09:55 +4.1%next day −1.0% · 5 days −0.8%
Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% Stifel Nicolaus $111 Buy +95.3% Reiterated 31.07.26on TipRanks 11:18 −3.5%next day −2.3% · 5 days −2.9%
Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% TD Cowen — Buy — Reiterated 30.07.26on TipRanks 13:45 +5.8%next day −3.5% · 5 days −5.9%
Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% Raymond James $78.06 → $117+49.9% Buy +105.8% Reiterated 13.01.26on TipRanks 10:24 −4.3%next day +2.7% · 5 days +0.5%
Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% Jefferies $154 Buy +170.9% Reiterated 19.12.25on TipRanks 15:15 −12.4%next day −1.2% · 5 days −3.3%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Disc Medicine

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%
1 year Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%
2 years Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%

Most profitable

3 months Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%
1 year Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%
2 years Thomas Smith★★★★★★★★★★Leerink Partners · #45
Hits 57%275 of 486 Average return +51.1%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $102 at a price of $65.46 (+56.2%); now: $102 at $56.84 (+79.8%).

$60.00$80.00$100Sep 15Oct 1Oct 15Top analysts$102Average target$102Price$56.84

PriceAverage targetTop analysts’ target

Recommendation trend

02040517Oct 25220Nov432Dec1024Jan 262425Feb2315Mar1611Apr79May718Jun723Jul521Aug515Sep610Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy777556
Buy91823211510
Hold000000
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-1.63 (from $-1.93 to $-1.28). Last quarter: $-1.54.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Disc Medicine
  • CEO: John D. Quisel
  • Employees: 165
  • 321 Arsenal Street, Watertown, MA, 02472, US
  • www.discmedicine.com

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗